STOCK TITAN

Tyra Biosciences, Inc. - TYRA STOCK NEWS

Welcome to our dedicated news page for Tyra Biosciences (Ticker: TYRA), a resource for investors and traders seeking the latest updates and insights on Tyra Biosciences .

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tyra Biosciences 's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tyra Biosciences 's position in the market.

Rhea-AI Summary
Tyra Biosciences, Inc. reports strong financials and progress in clinical development with TYRA-300, TYRA-200, and SURF301 studies. The company closed a $200 million financing, received FDA designations, and initiated new studies. Financially, TYRA has a pro-forma cash position of over $400 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.89%
Tags
-
Rhea-AI Summary
Tyra Biosciences, Inc. (TYRA) announced their participation in upcoming investor conferences to present a company overview and engage in one-on-one meetings with investors. The conferences include TD Cowen's 44th Annual Healthcare Conference, Jefferies Biotech On the Bay Summit, and Barclays 26th Annual Global Healthcare Conference. Todd Harris, CEO of TYRA, will lead the presentations and discussions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.17%
Tags
conferences
-
Rhea-AI Summary
Tyra Biosciences, Inc. (TYRA) CEO Todd Harris to present at Oppenheimer's 34th Annual Healthcare Life Sciences Conference on February 13, 2024. The company focuses on developing precision medicines targeting Fibroblast Growth Factor Receptor (FGFR) biology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.44%
Tags
conferences
Rhea-AI Summary
Tyra Biosciences, Inc. announced a private placement financing (PIPE) with gross proceeds of approximately $200 million, led by RA Capital Management. The financing involves the sale of approximately 15.4 million shares of common stock at a price of $13.01 per share. The company plans to use the net proceeds for clinical development, preclinical programs, drug discovery, and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.29%
Tags
none
-
Rhea-AI Summary
Tyra Biosciences, Inc. has received Rare Pediatric Disease Designation from the FDA for TYRA-300, an oral FGFR3 selective inhibitor, for the treatment of achondroplasia. This recognition highlights the severity of complications associated with achondroplasia in childhood and the lack of approved treatment options. TYRA plans to submit an IND application to the FDA in the second half of 2024 for a Phase 2 clinical trial for children with achondroplasia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.29%
Tags
none
-
Rhea-AI Summary
Tyra Biosciences, Inc. (Nasdaq: TYRA) has initiated the SURF201 Phase 1 study of TYRA-200, an FGFR1/2/3 inhibitor, and provided positive updates on its oral FGFR3-selective inhibitor, TYRA-300. The company plans to submit an IND application for the TYRA-300 Phase 2 ACH study to the FDA in the second half of 2024, indicating significant progress in their clinical-stage programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
none
Rhea-AI Summary
TYRA: Tyra Biosciences to Participate in 2023 Jefferies London Healthcare Conference, CEO Todd Harris to Speak on November 14th at 1:30 pm GMT
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3%
Tags
conferences
-
Rhea-AI Summary
Tyra Biosciences, Inc. (Nasdaq: TYRA) reported strong financial results with a cash position of $215.7 million as of Q3 2023. The company highlighted progress in SURF301 Phase 1/2 oncology study, preclinical data on TYRA-300 in achondroplasia, and plans to dose the first patient in TYRA-200 Phase 1 by YE 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
Tyra Biosciences to present TYRA-300 for achondroplasia at ASBMR and ASHG annual meetings
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.36%
Tags
none
Rhea-AI Summary
Tyra Biosciences to participate at Cantor Global Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.89%
Tags
conferences
Tyra Biosciences, Inc.

Nasdaq:TYRA

TYRA Rankings

TYRA Stock Data

864.02M
15.63M
5.34%
82.09%
5.38%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
CARLSBAD

About TYRA

tyra biosciences is a biotechnology company targeting new pathways of acquired resistance in oncology with purpose-built drugs.